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OBJECTIVES: In the secondary prevention of cardio-
vascular disease patient compliance with established 
risk-reducing factors remains inadequate. The primary
objective of the ORBITAL Study is to evaluate the impact
of a compliance enhancing program in patients receiving
statin therapy on long-term disease-related outcomes and
costs. Here the design and results of the pilot phases are
presented. METHODS: Approximately 7000 patients 
eligible for statin therapy (Joint European Guidelines) will
be enrolled nationwide in primary care practices in
Germany. Patients will be randomised into an interven-
tion group (12-month rosuvastatin plus compliance
program) and a control group (12-month rosuvastatin
alone). Disease-related costs, quality of life, cardiovascu-
lar events, and compliance will be assessed every 6
months during the 36 months follow-up. The compliance
program was developed based on previous studies, expert
advice, and pilot testing, and includes a start package
with a video and an information brochure, followed by
mailings and telephone calls. The program addresses
factors such as diet and lifestyle in addition to compli-
ance with pharmacotherapy. The information brochure
and telephone calls were evaluated in two subsequent
pilot phases. RESULTS: In the ﬁrst pilot phase, 23 of 25
contacted patients in a cardiac rehabilitation center con-
sidered the brochure to be easy to understand although
some criticized the use of too many medical terms. 17%
of patients considered the brochure to be too long. In 
the second pilot phase, 70 patients were randomised 
into intervention (n = 37) or control (n = 33) groups. The
majority of the intervention patients expressed high sat-
isfaction with the telephone calls although 10% indicated
the calls contained too much information and should be
shortened. CONCLUSION: With regard to the compli-
ance initiatives evaluated, the importance of not over-
loading patients with information became apparent.
Therefore, the compliance enhancing program was
revised accordingly for the main phase of the ORBITAL
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The chronic heart failure (CHF) is a chronic illness typi-
cally characterized by phases of clinical deterioration
requiring hospitalitation. The relief continuity is a fun-
damental element to better the effectiveness of the sani-
tary intervention. The Day-Hospital (DH), particularly,
could represent a valid tool to guarantee the relief conti-
nuity and to extend the phases of clinical stability in
patients with CHF. OBJECTIVES: The aim of this study
was to compare the managerial effectiveness and
Cost/Utility ratio between heart failure management
program delivered by day-hospital and usual care.
METHODS: Two hundred thirty-four consecutive
patients (M/F: 196/38; 56 ± 10 years) with chronic heart
failure (EF 29 ± 7%) referred to UHF were evaluated.
After clinical evaluation and therapuetic optimization,
122 patients received usual care (UC) and follow-up
(control every 6 months), despite 112 patients were acti-
vated in the DH. The DH program foresaw: 1) risk proﬁle
identiﬁcation; 2) objectives deﬁnition; 3) sanitary run
determination; 4) outcome markers measurement; and 5)
territory interaction (physician of family and/ or cardiol-
ogist of reference). Management (optimezed therapy and
Hospital readmission for heart failure (HRHF), func-
tional (NYHA functional class, Left ventricular ejection
fraction (LVEF)) and hard (cardiac death and urgent heart
transplantation) outcomes during 258 ± 88 days of
follow-up were considered. Cost/utility ratio of two
strategies were calculated. RESULTS: At baseline not
clinical and functional differences between two groups
were found. Hard cardiac events occured in 21/122
(17.2% on usual care (UC) and in 4/112 (3.6%) in DH
patients (p < .0007). The cost/utility ratio of two strate-
gies was similar (UC 2409$ vs DH $2244). The incre-
mental analysis pointed out for each gained Qaly in DH
a cost-saving of $1068. The cost-utility ratio for integra-
tion of Day Hospital to manage chronic heart failure was
$19,462(13,904–34,048). CONCLUSIONS: heart failure
management program delivered by day-hospital can
reduce mortality and morbidity of CHF patients. This
management strategy is cost-effective and has an equi-
table cost from a society point of view.
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